Explore
Everything on GPcardio.org in one place: lectures, updates and the literature scan.
A practical framework for using GLP-1 RAs, SGLT2i, and MRAs with contemporary immunosuppression in kidney transplant recipients.Ventricular arrhythmia-heart failure interaction and mortality in ICD recipients after myocardial infarction.Efficacy and safety of finerenone in non-diabetic chronic kidney diseaseResidual Risk From Remnant Cholesterol and Inflammation Despite Lipid-Lowering Therapy and Association With Incident Peripheral Artery Disease in Type 2 Diabetes.Impact of Undertreated Antithrombotic Therapy on Adverse Patient OutcomesSemaglutide and Cardiovascular DeathSYNCHRONIZE-CVOTATTAIN-OSATYDAL-TIMI 78 and CTX310ATTR cardiomyopathy in ChicagoPROGRESSLp(a)FRONTIERS EXPANSIONWarfarin After Seven DecadesDAPARHTIRONMET-HFpEFOptimPacingCOAST-AFRACE-CARSAssociations of Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia-Related Abnormalities With Adverse Clinical Outcomes Across Obesity States.Lp(a)HORIZONZEUSCOURAGE at 25 yearsSTREAMOPTIMAL-StrokeOPTIMAL-DIABETESEz-PAVE, second randomisationNon-invasive tests in metabolic dysfunction-associated steatotic liver diseaseUpdated Meta-Analysis of Left Atrial Appendage Closure Versus Oral Anticoagulation to Prevent Stroke in Atrial Fibrillation.Optimal exercise modalities and doses for blood pressure management in adults with prehypertension and hypertensionPractical Prevention of Heart Failure Across Stages A and BSodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and ErythropoiesisEffect of Obicetrapib on Glycaemia and New-Onset DiabetesAnticoagulation in Atrial Fibrillation With Previous Intracranial BleedingFinerenoneReal-world renoprotective effects of polyethylene glycol-loxenatide in type 2 diabetesImpact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Major Cardiovascular Events.Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial.
Looking beyond the expected patientGlucagon-Like Peptide-1 Receptor Agonists and Multi-hormone Receptor Modulators for Kidney Protection in Nondiabetic Kidney Disease.Vascular Risk Factors and Late-Onset Epilepsy.Management of Heart transplant recipients for the non Heart Transplant health care provider. A Clinical Consensus Statement of the Heart Failure Association (HFA) and the Association of Cardiovascular Nursing & Allied Professions (ACNAP) of the ESC.Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5Diagnostic Accuracy of NT-proBNP thresholds in Dyspneic Patients in the Emergency Department according to patients' characteristicsOutcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutideSGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 DiabetesProminent V Waves Augment Right Ventricular Afterload Independent of the Lung Vessels in Heart FailureCardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney DiseaseRecognition and control gaps in advanced cardiovascular-kidney-metabolic syndrome among United States adults.Anticancer Drugs and Cancer-Associated Thrombosis.
FIMMG National Congress Italy: strengthening dyslipidaemia management in primary careSystematic review of clinical guidance for lipid management in adults with or at risk of atherosclerotic cardiovascular diseaseCurrent Medical Therapy in Epicardial and Microvascular DiseasePharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum
Cardiorenal risk management in Primary care: Panel DiscussionGLP-1 Receptor Agonists in Heart FailureLong-term outcomes of childhood nephrotic syndrome.Stroke in the YoungFinerenone in MilanADA/EASD 2026 consensus on type 2 diabetes
Looking beyond the expected patientGlucagon-Like Peptide-1 Receptor Agonists and Multi-hormone Receptor Modulators for Kidney Protection in Nondiabetic Kidney Disease.Vascular Risk Factors and Late-Onset Epilepsy.Management of Heart transplant recipients for the non Heart Transplant health care provider. A Clinical Consensus Statement of the Heart Failure Association (HFA) and the Association of Cardiovascular Nursing & Allied Professions (ACNAP) of the ESC.Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5Diagnostic Accuracy of NT-proBNP thresholds in Dyspneic Patients in the Emergency Department according to patients' characteristicsOutcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutideSGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 DiabetesProminent V Waves Augment Right Ventricular Afterload Independent of the Lung Vessels in Heart FailureCardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney DiseaseRecognition and control gaps in advanced cardiovascular-kidney-metabolic syndrome among United States adults.Anticancer Drugs and Cancer-Associated Thrombosis.FIMMG National Congress Italy: strengthening dyslipidaemia management in primary careSystematic review of clinical guidance for lipid management in adults with or at risk of atherosclerotic cardiovascular diseaseCurrent Medical Therapy in Epicardial and Microvascular DiseasePharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrumCardiorenal risk management in Primary care: Panel DiscussionGLP-1 Receptor Agonists in Heart FailureLong-term outcomes of childhood nephrotic syndrome.Stroke in the YoungFinerenone in MilanADA/EASD 2026 consensus on type 2 diabetesNothing found. Try another word or remove a filter.